|
Vaccinex, Inc. (VCNX) DCF Avaliação
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Vaccinex, Inc. (VCNX) Bundle
A Explore Vaccinex, Inc. (VCNX) Prospects usando nossa calculadora DCF amigável! Digite suas suposições sobre crescimento, margens e despesas para calcular o valor intrínseco da Vaccinex, Inc. (VCNX) e aprimorar sua abordagem de investimento.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .5 | .1 | .9 | .1 | .6 | .6 | .6 | .7 | .7 | .7 |
| Revenue Growth, % | 0 | -90.44 | 1700 | -88.89 | 470 | 5.17 | 5.17 | 5.17 | 5.17 | 5.17 |
| EBITDA | -31.6 | -28.1 | -21.4 | -19.6 | -19.7 | -.6 | -.6 | -.7 | -.7 | -.7 |
| EBITDA, % | -6044.74 | -56110 | -2378 | -19606 | -3464.56 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .2 | .3 | .2 | .2 | .1 | .3 | .4 | .4 | .4 | .4 |
| Depreciation, % | 47.61 | 614 | 18.78 | 207 | 20.88 | 57.45 | 57.45 | 57.45 | 57.45 | 57.45 |
| EBIT | -31.9 | -28.4 | -21.6 | -19.8 | -19.9 | -.6 | -.6 | -.7 | -.7 | -.7 |
| EBIT, % | -6092.35 | -56724 | -2396.78 | -19813 | -3485.44 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 2.8 | 10.6 | 8.6 | 6.4 | 1.5 | .6 | .6 | .7 | .7 | .7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .9 | .2 | .0 | .2 | 1.0 | .5 | .5 | .5 | .6 | .6 |
| Account Receivables, % | 171.7 | 314 | 0 | 175 | 168.6 | 80 | 80 | 80 | 80 | 80 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0.000191204589 | 0.002 | 0 | 0.001 | 0 | 0.000638240918 | 0.000638240918 | 0.000638240918 | 0.000638240918 | 0.000638240918 |
| Accounts Payable | 3.2 | 3.2 | 1.1 | 1.5 | 2.0 | .6 | .6 | .7 | .7 | .7 |
| Accounts Payable, % | 613.38 | 6338 | 117.89 | 1518 | 357.72 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.1 | -.3 | .0 | -.1 | -.1 | -.3 | -.3 | -.3 | -.3 | -.3 |
| Capital Expenditure, % | -14.91 | -580 | -3.56 | -99 | -11.75 | -45.84 | -45.84 | -45.84 | -45.84 | -45.84 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -32.0 | -28.8 | -22.4 | -19.7 | -19.9 | -.6 | -.6 | -.7 | -.7 | -.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -29.5 | -28.1 | -24.2 | -19.3 | -20.1 | -1.5 | -.6 | -.6 | -.6 | -.6 |
| WACC, % | 8.19 | 8.19 | 8.19 | 8.18 | 8.19 | 8.19 | 8.19 | 8.19 | 8.19 | 8.19 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -3.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1 | |||||||||
| Terminal Value | -11 | |||||||||
| Present Terminal Value | -7 | |||||||||
| Enterprise Value | -10 | |||||||||
| Net Debt | -1 | |||||||||
| Equity Value | -9 | |||||||||
| Diluted Shares Outstanding, MM | 0 | |||||||||
| Equity Value Per Share | -19.44 |
What You Will Get
- Real VCNX Financial Data: Pre-filled with Vaccinex’s historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Vaccinex’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- 🔍 Real-Life VCNX Financials: Pre-filled historical and projected data for Vaccinex, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Vaccinex’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Vaccinex’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download: Obtain the pre-formatted Excel file featuring Vaccinex, Inc.'s (VCNX) financial data.
- Customize: Modify projections such as revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Automatically: Watch as intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various forecasts and evaluate results instantly.
- Make Decisions: Leverage the valuation insights to inform your investment approach.
Why Choose This Calculator for Vaccinex, Inc. (VCNX)?
- Accurate Data: Up-to-date Vaccinex financials provide trustworthy valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you from starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Simple layout and clear instructions make it accessible for all users.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and trustworthy valuation models for analyzing investments in Vaccinex, Inc. (VCNX).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Vaccinex, Inc. (VCNX).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling related to biotech.
- Biotech Enthusiasts: Gain insights into how biotech firms like Vaccinex, Inc. (VCNX) are valued in the financial market.
What the Template Contains
- Preloaded VCNX Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.